OCT 11, 2017 1:30 PM PDT

Pancreatic Cancer: Challenges and Solutions

Speaker

Abstract

Pancreatic cancer is one of the “deadly” cancers, defined as those with a 5-year relative survival rate of less than 50%.  Although ranking 12th in terms of incidence, it is on track to become the second leading cause of cancer deaths by 2020.  The Pancreatic Cancer Action Network (PanCAN) set a goal of doubling survival by 2020, identified 5 specific challenges that need to be addressed, and initiated approaches to contribute to their solution.  There are not enough researchers or research, the clinical trial enrollment rate is too low, clinical trials need to be streamlined and focused, there is insufficient public awareness, and most patients are seen in the community setting where there is little experience with the disease.  Through advocating for government resources, the NCI allocation to pancreatic cancer has increased 5-fold since 1999, with several new research initiatives that resulted from the passage of the Recalcitrant Cancer Research Act in 2013.  Patient Central associates served more than 33,000 patients and families last year, providing disease and treatment information, support resources, and clinical trial searches.  The Patient Registry collects information from individual patients, learns best practices, and disseminates information on topics such as the use of pancreatic enzyme replace therapy to the scientific community.  The Know Your Tumor ® initiative has enrolled more than 1300 patients from across the US, and delivered almost 700 reports thus far detailing the results from genomic and proteomic analysis of tumor tissue with treatment options based on the molecular profiling and consideration of treatment history.  These results indicate that 25% of pancreatic cancer patients have “actionable alterations” that indicate a targeted therapy, and that the median progression-free survival of patients that utilize a report-directed targeted therapy increased by 46% over those with no highly actionable alteration.  The clinical trial landscape in pancreatic cancer has changed over the past 5 years, with a doubling of those trials that test a targeted therapy and an increase in trials for recurrent disease.  The accrual of pancreatic adenocarcinoma patients to clinical trials increased from 3.8% in 2011 to 4.2% in 2014; this is at least in part attributed to increased awareness of clinical trials through PanCAN’s Clinical Trial Finder (12% of those who access this service enroll in a clinical trial) and Know Your Tumor ® initiatives (21% of participants enroll in a clinical trial).  PanCAN is initiating Precision PromiseSM , a clinical trial and research platform with the mission of continuously and rapidly evaluating novel treatment options for pancreatic cancer.  Public awareness of the disease is raised with a volunteer presence in 90 communities throughout the US and leadership in the World Pancreatic Cancer Coalition.  A comprehensive approach to the disease, through Government Affairs, Research Grants & Clinical Initiatives, Patient Services, and Community Engagement, has resulted in significant advances on multiple fronts, helping to propel the field towards achieving the goal of doubling survival by 2020 and using that as a platform for continued and sustained improvements in the years to come.


Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
JUL 15, 2021 8:00 AM PDT
C.E. CREDITS
JUL 15, 2021 8:00 AM PDT
Date: July 15, 2021 Time: 8:00am (PDT), 11:00am (EDT) High dimensional full spectrum flow cytometry grants unprecedented access to previously unattainable parameters in cellular biology. Flu...
NOV 17, 2021 8:00 AM PST
C.E. CREDITS
NOV 17, 2021 8:00 AM PST
Date: November 17, 2021 Time: 8:00am (PDT), 11:00am (EDT) From waste disposal to promising biomarkers and therapeutic agents, exosomes and other extracellular vesicles are valuable in resear...
JUL 15, 2021 9:00 AM PDT
JUL 15, 2021 9:00 AM PDT
Date: July 15, 2021 Time: 9:00am (PDT), 12:00pm (EDT) The Pisces workflow robust, easy-to-use, end-to-end multi-omics solution for highly multiplexed targeted Spatial RNA analysis. VeranomeB...
OCT 11, 2017 1:30 PM PDT

Pancreatic Cancer: Challenges and Solutions


Specialty

Cancer

Antibodies

Immuno-Oncology

Gene Sequencing

Cancer Diagnostics

Dna Sequencing

Biomarkers

Cell Culture

Oncology

Cancer Research

Dna

Clinical Diagnostics

Immunology

Gene Expression

Biotechnology

Geography

North America50%

Europe50%

Registration Source

Website Visitors100%

Job Title

Student50%

Clinical Laboratory Scientist50%

Organization

Biotech Company50%

Academic Institution50%


Show Resources
Loading Comments...
Show Resources